Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 5, 2009 - Issue 4
Submit an article Journal homepage
4,264
Views
242
CrossRef citations to date
0
Altmetric
Reviews

Antisense oligonucleotide pharmacokinetics and metabolism

Richard S Geary Isis Pharmaceuticals, Inc., 1896 Rutherford Rd, Carlsbad, CA 92008, USA +1 760 603 2501; +1 760 603 4650; [email protected]
Pages 381-391 | Published online: 21 Apr 2009

Bibliography

  • Cossum PA, Sasmor H, Dellinger D, et al. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 1993;267(3):1181-90
  • Cossum AP, Troung L, Owens RS, et al. Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J Pharmacol Exp Ther 1994;269(1):89-94
  • Zhang R, Diasio BR, Lu Z, et al. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (Gem 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 1995;49(7):929-39
  • Agrawal S, Temsamani J, Galbraith W, Tang J, et al. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 1995;28(1):7-16
  • Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 1991;88:7595-9
  • Phillips JA, Craig SJ, Bayley D, et al. Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 1997;54(6):657-68
  • Geary RS, Leeds JM, Fitchett J, et al. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab Dispos 1997;25(11):1272-81
  • Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA, et al. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti Cancer Drug Design 1997;12(5):383-93
  • Leeds JM, Geary RS. Pharmacokinetic properties of phosphorothioate oligonucleotides in humans, in antisense research and applications. In: Crooke ST, editor, Springer: Heidelberg; 1998. p. 217-31
  • Leeds JM, Geary RS, Henry SP, et al. Pharmacokinetic properties of phosphorothioate oligonucleotides. Nucleosides Nucleotides 1997;16:1689-93
  • Levin AA. A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999;1489(1):69-84
  • Levin AA, Geary RS, Leeds JM, et al. The pharmacokinetics and toxicity of phosphorothioate oligonucleotides, in biotechnology and safety assessment. In: Thomas JA, editor, Taylor & Francis: Philadelphia, PA. 1998. p. 151-75
  • Geary RS, Khatsenko O, Bunker K, et al. Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J Pharmacol Exp Ther 2001;296(3):898-904
  • Geary RS, Mathison B, Ushiro-Watanabe T, et al. Second generation antisense oligonucleotide pharmacokinetics and mass balance following intravenous administration in rats in Society Of Toxicology. San Francisco, CA: Oxford University Press, 2001
  • Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 2003;31(11):1419-28
  • Zhang R, Lu Z, Zhao H, et al. In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats. Biochem Pharmacol 1995;50(4):545-56
  • Yu RZ, Geary RS, Monteith DK, et al. Tissue disposition of a 2′-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J Pharm Sci 2004;93:48-59
  • Yu RZ, Kim TW, Hong A, et al. Cross-species pharmacokinetic comparison from mouse to man of a second generation antisense oligonucleotide ISIS 301012, targeting human ApoB-100. Drug Metab Dispos 2007;35:460-8
  • Kilk K, Langel U. Cellular delivery of peptide nucleic acid by cell-penetrating peptides. Methods Mol Biol 2005;298:131-41
  • Lendvai G, Velikyan I, Estrada S, et al. Biodistribution of 68Ga-labeled LNA-DNA mixmer antisense oligonucleotides for rat chromogranin-A. Oligonucleotides 2008;18(1):33-49
  • Amantana A, Iversen PL. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr Opin Pharmacol 2005;5(5):550-5
  • Arora V, Devi GR, Iversen PL. Neutrally charged phoshorodiamidate morpholino antisense oligomers: uptake, efficay and pharmacokinetics. curr pharm Biotechnol 2004;5:1-9
  • Senn C, Hangartner C, Moes S, Guerini D, Hofbauer KG, et al. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides. Eur J Pharmacol 2005;522(1-3):30-7
  • Braasch DA, Paroo Z, et al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 2004;14(5):1139-43
  • Manoharan M. RNA interference and chemically modified small interfering RNAs. Curr Opin Chem Biol 2004;8(6):570-5799
  • Manoharan M, Rajeev KG. Utilizing chemistry to harness RNA interference pathways for therapeutics: chemically modified siRNAs and antagomirs, in antisense drug technology, principles, strategies and applications. In: Crooke ST, editor, Taylor & Francis Group: Boca Raton, FL. 2007. p. 437-64
  • Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008;26(5):561-9
  • Yu RZ, Lemonidis KM, Graham MJ, et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 2009;77(5):910-9
  • Bhanot S. Developing antisense drugs for metabolic diseases: a novel therapeutic approach, in antisense drug technology, principles, strategies and applications. In: Crooke ST, editor, Taylor & Francis Group: Boca Raton, FL. 2007. p. 641-64
  • Geary RS, Yu RZ, Siwkowski A, Levin AA, et al. Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2′ - O-(2-Methoxyethyl)-Modified antisense oligonucleotides in animals and man, in antisense drug technology, principles, strategies and applications. In: Crooke ST, editor, Taylor & Francis Group: Boca Raton, FL. 2007. p. 305-26
  • Yu RZ, Geary RS, Levin AA. Pharmacokinetics and pharmacodynamics of antisense oligonucleotides, in encyclopedia of molecular cell biology and molecular medicine. In: Meyers RA, editor, Wiley-VCH: Weinheim, Germany; 2007
  • Yu RZ, Zhang H, Geary RS, et al. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J Pharmacol Exp Ther 2001;296(2):388-95
  • Zhang H, Cook J, Nickel J, et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 2000;18(8):862-7
  • Geary RS, Ushiro-Watanabe T, Truong L, et al. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 2001;296(3):890-7
  • Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008;105(33):11915-20
  • Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441(7089):111-4
  • Khatsenko O, Morgan R, Troung L, et al. Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length. Antisense Nucleic Acid Drug Dev 2000;10(1):35-44
  • Tillman LG, Geary RS, Hardee GE. Oral delivery of antisense oligonucleotides in man. J Pharm Sci 2008;97(1):225-36
  • Hardee GE, Tillman LG, Geary RS. Routes and formulations for delivery of antisense oligonucleotides, in antisense drug technology, principles, strategies and applications. In: Crooke ST, editor, Taylor & Francis Group: Boca Raton, FL. 2007. p. 217-36
  • Arora V, Knapp DC, Reddy MT, Weller DD, Iversen PL, et al. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J Pharm Sci 2002;91(4):1009-18
  • Perry CM, Barman Balfour JA. Fomivirsen. Drugs 1999;57(3):375-80
  • de Smet MD, Meenken CJ, van den Horn GJ. Fomivirsen – a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocular Immunol Inflamm 1999;7(3-4):189-98
  • Geary RS, Henry SP, Grillone LR. Fomivirsen: clinical pharmacology and potential drug interactions. Clin Pharmacokinet 2002;41(4):255-60
  • Bejanian M, Lieberman RM, Goldstein DA, et al. A pharmacokinetic study of intravitreal fomivirsen (Vitravene™) in patients with CMVR. in ARVO 1999 annual meeting. Fort Lauderdale, FL; 1999
  • Reich S, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003;9:210-6
  • Khaitov MR, Akimov VS, Faizuloev EB, et al. Inhibition of Respiratory Syncytial Virus (RSV) Replication in Cell Culture by Small Interfering RNA (siRNA). J Allerty Clin Immunol 2007;119(1):S233-S234
  • Liszewski K. RNAi in drug discovery & therapeutics – combining tools and technologies to improve delivery and efficacy of key compounds. Genet Eng Biotechnol News 2006;26(16)
  • Karras JG, Crosby JR, Guha M, et al. Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. Am J Respir Cell Mol Biol 2007;36(3):276-85
  • Templin MV, Levin AA, Graham MJ, et al. Pharmacokinetic and toxicity profile of a phosphorohtioate oligonucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev 2000;10(5):359-68
  • Ali S, Leonard SA, Kukoly CA, et al. Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. Am J Respir Crit Care Med 2001;163(4):989-93
  • Crosby JR, Guha M, Tung D, et al. Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice. J Pharmacol Exp Ther 2007;321(3):938-46
  • Miner P, Wedel M, Bane B, Bradley J, et al. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004;19(3):281-6
  • Miner PB Jr, Geary RS, Matson J, et al. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther 2006;23(10):1427-34
  • Butler M, Hayes CS, Chappell A, et al. Spinal distribution and metabolism of 2′-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats. Neuroscience 2005;131(3):705-15
  • Zhang M, Creese I. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavorial correlates. Neuroscience Lett 1993;(161):223-6
  • Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006;116(8):2290-6
  • Watanabe TA, Geary RS, Levin AA. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 2006;16(2):169-80
  • Watanabe TA, Geary RS, Levin AA. In vitro protein binding and drug interaction studies of an antisense oligonucleotide (aso), Isis 113715, targeting human Ptb1b Mrna. in AAPS Annual Meeting and Exposition. Baltimore MD: American Association of Pharmaceutical Scientists; 2004
  • Geary RS, Bradley JD, Watanabe T, et al. Lack of pharmacokinetic interaction for ISIS 113715, a 2′-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet 2006;45(8):789-801
  • Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009;48(1):39-50
  • Levin AA, Yu RZ, Geary RS. Basic principles of the pharmacokinetics of antisense oligonucleotide drugs, in antisense drug technology, principles, strategies and applications.In: Crooke ST, editor, Taylor & Francis Group: Boca Raton, FL. 2007. p. 183-215
  • Lorenz P, Misteli T, Baker BF, Bennett CF, Spector DL, et al. Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acid Res 2000;28(2):582-92
  • Graham MJ, Crooke ST, Lemonidis KM, et al. Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochem Pharmacol 2001;62:297-306
  • Graham MJ, Crooke ST, Monteith DK, et al. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther 1998;286(1):447-58
  • Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114(16):1729-35
  • Griffey RH, Greig MJ, Gaus HJ, et al. Characterization of oligonucleotide metabolism in vivo via liquid chromatography/electrospray tandem mass spectrometry with a quadrople ion trap mass spectrometer. J Mass Spectrom 1997;32:305-13
  • Gaus HJ, Owens SR, Winniman M, Cooper S, Cummins LL, et al. On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal Chem 1997;69(3):313-9
  • Crooke RM, Graham MJ, Martin MJ, et al. Metabolism of antisense oligonucleotides in rat liver homogenates. J Pharmacol Exp Ther 2000;292(1):140-9
  • Wojcik M, Cieslak M, Stec WJ, Goding JW, et al. Nucleotide pyrophosphatase/phosphodiesterase 1 is responsible for degradation of antisense phosphorothioate oligonucleotides. Oligonucleotides 2007;17(1):134-45
  • Adjei AA, Erlichman C, Sloan JA, et al. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras in combination with gemcitabine in patients with advanced cancer. 2000: p. 722
  • Yuen AR, Advani R, Fisher G, et al. A phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer. in American Society of Clinical Oncology 36th Annual Meeting. New Orleans, LA; 2000
  • Mani S, Rudin CM, Kunkel K, et al. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res 2002;8(4):1042-8
  • Adjei AA, Dy GK, Erlichman C, et al. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 2003;9(1):115-23
  • Moore J, Seiter K, Kolitz J, et al. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leukemia Res 2006;30(7):777-83
  • Vickers TA, Koo S, Bennett CF, et al. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. Journal of Biological Chemistry 2003;278(9):7108-18
  • Sewell LK, Geary RS, Baker BF, et al, Phase I trial of ISIS 104838, β 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. Journal of Pharmacology and Experimental Therapeutics 2002;303(3):1334-1343

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.